Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

India's Biotech Department Steps In To Boost Biosimilars Programs Of Indian Companies

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Realizing the importance of developing inexpensive biotech treatments, India's Department of Biotechnology has for the first time invited proposals from Indian companies to work together on the development of biosimilar products
Advertisement

Related Content

Lack Of Risk Funding Impedes India's Discovery R&D Growth But Mindset Change Is Making A Difference, Report Says
Lack Of Risk Funding Impedes India's Discovery R&D Growth But Mindset Change Is Making A Difference, Report Says
Launch Delays In U.S. Dampen Dr. Reddy's Q1 Earnings But Money Starts Flowing From GSK Deal; Analysts Confident On Future Outlook
Launch Delays In U.S. Dampen Dr. Reddy's Q1 Earnings But Money Starts Flowing From GSK Deal; Analysts Confident On Future Outlook
India's Cipla Unwraps Its Biosimilars Ambitions With A Presence In India And Shanghai; Earmarks $65 Million In First Push
Advertisement
UsernamePublicRestriction

Register

SC075694

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel